Stem Cell Bioprocessing and Manufacturing
The next healthcare revolution will apply regenerative medicines using human cells and tissues. The aim of the regenerative medicine approach is to create biological therapies or substitutes in vitro for the replacement or restoration of tissue function in vivo lost through failure or disease. Howev...
Saved in:
| HerausgeberIn: | |
|---|---|
| Sonstige: | |
| Year of Publication: | 2020 |
| Language: | English |
| Physical Description: | 1 electronic resource (170 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04772nam-a2201153z--4500 | ||
|---|---|---|---|
| 001 | 993546126904498 | ||
| 005 | 20231214133047.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202105s2020 xx |||||o ||| 0|eng d | ||
| 035 | |a (CKB)5400000000045508 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/68946 | ||
| 035 | |a (EXLCZ)995400000000045508 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Cabral, Joaquim M. S. |4 edt | |
| 245 | 1 | 0 | |a Stem Cell Bioprocessing and Manufacturing |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2020 | ||
| 300 | |a 1 electronic resource (170 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a The next healthcare revolution will apply regenerative medicines using human cells and tissues. The aim of the regenerative medicine approach is to create biological therapies or substitutes in vitro for the replacement or restoration of tissue function in vivo lost through failure or disease. However, whilst science has revealed the potential, and early products have shown the power of such therapies, there is an immediate and long-term need for expertise with the necessary skills to face the engineering and life science challenges before the predicted benefits in human healthcare can be realized. Specifically, there is a need for the development of bioprocess technology for the successful transfer of laboratory-based practice of stem cell and tissue culture to the clinic as therapeutics through the application of engineering principles and practices. This Special Issue of Bioengineering on Stem Cell Bioprocessing and Manufacturing addresses the central role in defining the engineering sciences of cell-based therapies, by bringing together contributions from worldwide experts on stem cell biology and engineering, bioreactor design and bioprocess development, scale-up, and manufacturing of stem cell-based therapies. | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a electrospinning | ||
| 653 | |a live-cell electrospinning | ||
| 653 | |a tissue engineering | ||
| 653 | |a cell seeding | ||
| 653 | |a high voltage | ||
| 653 | |a viability | ||
| 653 | |a allogeneic cell therapy | ||
| 653 | |a induced pluripotent stem cell | ||
| 653 | |a human embryonic stem cell | ||
| 653 | |a cell aggregate | ||
| 653 | |a expansion | ||
| 653 | |a differentiation | ||
| 653 | |a scalable manufacturing | ||
| 653 | |a scale up | ||
| 653 | |a single-use bioreactor | ||
| 653 | |a Vertical-Wheel | ||
| 653 | |a U-shaped vessel | ||
| 653 | |a computational fluid dynamics | ||
| 653 | |a shear stress | ||
| 653 | |a turbulent energy dissipation rates | ||
| 653 | |a homogeneous hydrodynamic environment | ||
| 653 | |a human pluripotent stem cells | ||
| 653 | |a hepatic cell lineages | ||
| 653 | |a hepatocyte differentiation | ||
| 653 | |a non-parenchymal liver cells | ||
| 653 | |a liver organoids | ||
| 653 | |a disease modeling | ||
| 653 | |a drug screening | ||
| 653 | |a olfactory ensheathing cells | ||
| 653 | |a spinal cord injury | ||
| 653 | |a neural regeneration | ||
| 653 | |a cell therapies | ||
| 653 | |a adipose stem cells | ||
| 653 | |a neurotrophic factors | ||
| 653 | |a growth factors | ||
| 653 | |a peripheral nerve injuries | ||
| 653 | |a fibrin nerve conduits | ||
| 653 | |a hydrogels | ||
| 653 | |a stem cells delivery | ||
| 653 | |a axonal regeneration | ||
| 653 | |a Schwann cells | ||
| 653 | |a stromal vascular fraction | ||
| 653 | |a stem cell | ||
| 653 | |a adipose-derived stem cell | ||
| 653 | |a infrapatellar fat pad | ||
| 653 | |a knee | ||
| 653 | |a arthroscopy | ||
| 653 | |a arthrotomy | ||
| 653 | |a bioreactor | ||
| 653 | |a hMSCs | ||
| 653 | |a microcarrier | ||
| 653 | |a bioprocess | ||
| 653 | |a embryonic stem cells | ||
| 653 | |a mesenchymal stromal cells | ||
| 653 | |a blood platelets | ||
| 653 | |a cell culture techniques | ||
| 653 | |a progenitor cells | ||
| 653 | |a human adipose stem cells (hASCs) | ||
| 653 | |a serum- and xeno-free conditions | ||
| 653 | |a UrSuppe stem cell culture medium | ||
| 653 | |a autologous therapy | ||
| 653 | |a kinetic growth modeling | ||
| 653 | |a segregated and unstructured growth model | ||
| 653 | |a model predictive control | ||
| 653 | |a bio-process | ||
| 653 | |a cell growth | ||
| 653 | |a lactate | ||
| 653 | |a advanced therapy medicinal products | ||
| 776 | |z 3-03943-038-6 | ||
| 776 | |z 3-03943-039-4 | ||
| 700 | 1 | |a Lobato da Silva, Cláudia |4 edt | |
| 700 | 1 | |a Diogo, Maria Margarida |4 edt | |
| 700 | 1 | |a Cabral, Joaquim M. S. |4 oth | |
| 700 | 1 | |a Lobato da Silva, Cláudia |4 oth | |
| 700 | 1 | |a Diogo, Maria Margarida |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:41:17 Europe/Vienna |f system |c marc21 |a 2022-04-04 09:22:53 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338180560004498&Force_direct=true |Z 5338180560004498 |b Available |8 5338180560004498 | ||